Business
PreveCeutical Medical Announces Frontiers Media SA Publication Featuring Data from its Analgesic Program for the Treatment of Peptide-based Therapeutics for Moderate to Severe Pain
Synthesized Kappa Opioid Receptors (KOP) Appear to be Devoid of Many Problematic Mu Receptor Si...
About this update from Preveceutical Medical Inc
[{"type":"text","content":"PreveCeutical Medical Announces Frontiers Media SA Publication Featuring Data from its Analgesic Program for the Treatment of Peptide-based Therapeutics for Moderate to Severe PainSynthesized Kappa Opioid Receptors (KOP) Appear to be Devoid of Many Problematic Mu Receptor Side-effects Such as Tolerance, Addiction, Sedation, and Euphoria/Dysphoria,KOP Peptides Showed Significant Opioid-like Antinociception Comparable to Morphine and U50844HPreveCeutical's Pain Management Peptides Program Published in the Swiss Medical Journal.Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the \"Company\" or \"PreveCeutical\") is pleased to announce the full independent peer-reviewed publication of an article on the design and development of its non-addictive analgesic program (\"Analgesic Program\"). The article entitled, \"Design and development of novel, short, stable dynorphin-based opioid agonists for safer analgesic therapy,\" was published in Frontiers Media SA (the \"Frontiers\") and can be found here. The article is published under the journal's open-access scheme.The Analgesic Program was initiated in July 2018 and was designed to discover and develop peptide-based therapeutics for moderate to severe pain. The program was successfully completed in March 2021, and in March 2023, PreveCeutical began preparation with a world-leading CRO to advance the Analgesic Program into Phase 1 clinical trials.The class of compounds, peripheral Kappa opioid receptor (KOPr) agonists, are considered potential analgesics without the dose-limiting central nervous system-mediated side effects. The potency and duration of action of peptides identified in the study were comparable to the clinical standard morphine, in-vivo.PreveCeutical's Chair and Chief Executive Officer, Mr. Stephen Van Deventer, stated, \"Having an independent peer-reviewed article from PreveCeutical's program and having it published in the prestigious Frontiers is a big milestone for our non-addictive analgesic program. Therapies based on these potentially non-addictive peptides will be important in addressing the current opioid crisis.\"Frontiers is the leading international general pharmacology journal representing the 3rd most-cited and 6th largest open science research platform publisher. It publishes hi...